Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HLA-A2-restricted melanoma-specific peptides vaccine GRN-1201

A cancer peptide vaccine composed of four human leukocyte antigen (HLA)-A2 (HLA-A*02)-restricted peptides derived from four specific and separate tumor-associated antigens (TAAs) expressed by melanoma cells, with potential antineoplastic activity. Upon administration of the HLA-A2-restricted melanoma-specific peptides vaccine, the melanoma specific antigens in the vaccine activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the HLA-A2-positive melanoma cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	cancer vaccine GRN-1201 peptide cancer vaccine GRN-1201 peptide vaccine GRN-1201
Code name:	GRN-1201

HLA-A2-restricted melanoma-specific peptides vaccine GRN-1201

Search NCI's Drug Dictionary